Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alector's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alector's regulatory disclosures and financial reporting.
Paula Hammond, a director of Alector, Inc. (ALEC), reported a planned sale of common stock executed on 08/26/2025 under a Rule 10b5-1 trading plan adopted on May 27, 2025. The filing shows 14,000 shares were sold at a weighted average price of $2.357, with individual trade prices ranging from $2.31 to $2.385. After the reported sales, Hammond beneficially owned 74,909 shares directly. The Form 4 was submitted by one reporting person and signed by Grace Wong-Sarad by power of attorney on 08/27/2025. All details in this summary are taken directly from the Form 4 provided.
Alector, Inc. (ALEC) filed a Form 144 reporting a proposed sale of 14,000 shares of common stock, scheduled to be sold through Morgan Stanley Smith Barney LLC on 08/26/2025 on Nasdaq for an aggregate market value of $32,996.60. The filer reports total shares outstanding of 101,212,329. The shares were acquired as restricted stock from the issuer on 06/11/2025, with payment dated the same day. No securities sales by the filer in the past three months are reported. The filer affirms they are not aware of undisclosed material adverse information and includes the standard signature and certification language required by Rule 144.
Alector, Inc. Schedule 13G/A summary: This amendment reports that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and two individuals (Peter Kolchinsky and Rajeev Shah) each beneficially own 0 shares of Alector common stock, representing 0.0% of the class as of the reporting date. The filing lists the reporting persons' principal business address at c/o RA Capital Management, 200 Berkeley Street, Boston, MA, and states the entities are Delaware partnerships while the individuals are U.S. citizens. The reporting persons expressly disclaim status as a group and confirm the securities were not acquired to influence control of the issuer. The filing incorporates a Joint Filing Agreement by reference.
Alector, Inc. (ALEC) submitted a Form 144 reporting a proposed sale of 76,446 common shares with an aggregate market value of $152,892.00, against 101,212,329 shares outstanding. The filing states the shares were acquired as restricted stock on 03/01/2023 and lists an approximate sale date of 08/08/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The notice also discloses a prior sale of 16,488 shares on 06/02/2025 for gross proceeds of $22,065.89. The signer represents there is no undisclosed material adverse information and includes standard Rule 144 attestations.